niacin has been researched along with Arterial Diseases, Carotid in 23 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 7.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "Niacin is a safe and effective means of raising HDL, yet its role in stroke prevention is not well characterized." | 6.44 | Niacin for stroke prevention: evidence and rationale. ( Keener, A; Sanossian, N, 2008) |
| "Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown." | 5.11 | Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. ( Grace, KA; Lee, HJ; Lee, JK; Sullenberger, LE; Taylor, AJ, 2004) |
| "To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels." | 3.76 | Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. ( Barter, PJ; Charlton, F; Rye, KA; Witting, P; Wu, BJ; Yan, L, 2010) |
| "Niacin has multiple lipoprotein effects that may provide cardiovascular benefit when added to statin monotherapy." | 2.74 | Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. ( Airan-Javia, SL; Mohler, E; Reilly, MP; Tadesse, M; Wolf, RL; Wolfe, ML, 2009) |
| "Niacin is a safe and effective means of raising HDL, yet its role in stroke prevention is not well characterized." | 2.44 | Niacin for stroke prevention: evidence and rationale. ( Keener, A; Sanossian, N, 2008) |
| "Niacin is a unique lipid-lowering medication with a capacity to lower low-density lipoprotein cholesterol (LDL-c), triglyceride and increase HDL-c." | 1.36 | What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? ( Ahmed, MH, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sibley, CT | 1 |
| Vavere, AL | 1 |
| Gottlieb, I | 1 |
| Cox, C | 1 |
| Matheson, M | 1 |
| Spooner, A | 1 |
| Godoy, G | 1 |
| Fernandes, V | 1 |
| Wasserman, BA | 2 |
| Bluemke, DA | 2 |
| Lima, JA | 2 |
| Lim, GB | 1 |
| Khera, AV | 1 |
| Patel, PJ | 1 |
| Reilly, MP | 2 |
| Rader, DJ | 1 |
| Ronsein, GE | 1 |
| Hutchins, PM | 1 |
| Isquith, D | 1 |
| Vaisar, T | 1 |
| Zhao, XQ | 2 |
| Heinecke, JW | 1 |
| Keener, A | 1 |
| Sanossian, N | 1 |
| Airan-Javia, SL | 1 |
| Wolf, RL | 1 |
| Wolfe, ML | 1 |
| Tadesse, M | 1 |
| Mohler, E | 1 |
| Jaffer, FA | 1 |
| Lee, JM | 1 |
| Robson, MD | 1 |
| Yu, LM | 1 |
| Shirodaria, CC | 1 |
| Cunnington, C | 1 |
| Kylintireas, I | 1 |
| Digby, JE | 1 |
| Bannister, T | 1 |
| Handa, A | 1 |
| Wiesmann, F | 1 |
| Durrington, PN | 1 |
| Channon, KM | 1 |
| Neubauer, S | 1 |
| Choudhury, RP | 1 |
| Parhofer, K | 1 |
| Cobble, M | 1 |
| Bale, B | 1 |
| Wu, BJ | 1 |
| Yan, L | 1 |
| Charlton, F | 1 |
| Witting, P | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Ahmed, MH | 1 |
| MANGUEL, M | 1 |
| RAMOS, AO | 1 |
| GORDON, DM | 1 |
| Taylor, AJ | 3 |
| Sullenberger, LE | 3 |
| Lee, HJ | 3 |
| Lee, JK | 2 |
| Grace, KA | 2 |
| Grundy, SM | 1 |
| Desai, MY | 1 |
| Rodriguez, A | 1 |
| Gerstenblith, G | 1 |
| Agarwal, S | 1 |
| Kennedy, M | 1 |
| Phan, BA | 1 |
| Chu, B | 1 |
| Polissar, N | 1 |
| Hatsukami, TS | 1 |
| Yuan, C | 1 |
| Zhu, D | 1 |
| Riasina, TV | 1 |
| Korshunova, TS | 1 |
| Polianskiĭ, NB | 1 |
| Muranov, KO | 1 |
| Blankenhorn, DH | 1 |
| Selzer, RH | 1 |
| Crawford, DW | 1 |
| Barth, JD | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Mack, WJ | 1 |
| Alaupovic, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy[NCT01212900] | Phase 4 | 230 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273] | Phase 4 | 217 participants (Actual) | Interventional | 2001-05-01 | Completed | ||
| Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function[NCT00232531] | 70 participants | Interventional | 2004-09-30 | Active, not recruiting | |||
| ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657] | Phase 4 | 400 participants (Anticipated) | Interventional | 2006-11-30 | Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.) | ||
| [NCT00000599] | Phase 3 | 0 participants | Interventional | 1980-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Wall volume of internal carotid arteries was measured using magnetic resonance imaging. Participants will undergo 2D and 3D carotid MRI using a 3 Tesla scanner and surface carotid coils. Participants with mild or no atherosclerosis, defined as the lowest tertile of wall volume, will have statin therapy adjusted to a target range of 100-130 mg/dL. Participants in the middle tertile will receive statin therapy adjusted to achieve a target LDL 70-100 mg/dL. Participants with the most severe atherosclerosis will receive statin therapy to an LDL target between 40 and 70 mg/dL. Participants in the Standard arm will have lipid sub-fraction targets determined according to estimated 10 year cardiovascular risk, as per standard NCEP guidelines. (NCT01212900)
Timeframe: 24 months
| Intervention | Other - mm^3 ( cubic millimeter ) (Mean) |
|---|---|
| Imaging | -3.52 |
| Standard | -5.91 |
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | mm^3/year (Mean) |
|---|---|
| 1 - Single Therapy Group | -4.6 |
| 2 - Double Therapy Group | -15.1 |
| 3 - Triple Therapy Group | -9.4 |
"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3
| Intervention | percentage change/year (Mean) | |
|---|---|---|
| LRNC change | Wall Volume change | |
| 1 - Single Therapy Group | -1.6 | -0.6 |
| 2 - Double Therapy Group | -3.6 | -1.4 |
| 3 - Triple Therapy Group | -2.8 | -1.2 |
Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Composite Measured at Year 3 | Composite Measured at Year 4 (cumulative) | Composite Measured at Year 5 (cumulative) | |
| 1 - Single Therapy Group | 6 | 7 | 9 |
| 2 - Double Therapy Group | 6 | 11 | 11 |
| 3 - Triple Therapy Group | 7 | 9 | 9 |
2 reviews available for niacin and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Niacin for stroke prevention: evidence and rationale.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Humans; Niaci | 2008 |
Carotid intima-media thickness: knowledge and application to everyday practice.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Confide | 2010 |
9 trials available for niacin and Arterial Diseases, Carotid
| Article | Year |
|---|---|
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study.
Topics: Aged; Carotid Artery Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydro | 2013 |
Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Carotid Artery Dise | 2016 |
Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.
Topics: Aged; Aged, 80 and over; Carotid Artery Diseases; Dose-Response Relationship, Drug; Drug Therapy, Co | 2009 |
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
Topics: Aged; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Confounding Factors, Epidemiologi | 2009 |
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Coronary Diseas | 2004 |
Association of cholesterol subfractions and carotid lipid core measured by MRI.
Topics: Aged; Carotid Artery Diseases; Cholesterol; Female; Humans; Hypolipidemic Agents; Magnetic Resonance | 2005 |
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3.
Topics: Aged; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Delayed-Action Preparations; Drug | 2006 |
Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
Topics: Aged; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, | 2007 |
Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
Topics: Adult; Arteriosclerosis; Carotid Artery Diseases; Carotid Artery, Common; Colestipol; Drug Therapy, | 1993 |
12 other studies available for niacin and Arterial Diseases, Carotid
| Article | Year |
|---|---|
Atherosclerosis: Addition of niacin to optimal statin therapy does not affect plaque regression.
Topics: Carotid Artery Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Re | 2013 |
The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.
Topics: Aged; Carotid Artery Diseases; Cholesterol, HDL; Clinical Trials as Topic; Female; Humans; Hypolipid | 2013 |
Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Admin | 2009 |
[Statin plus niacin or ezetimibe? What combination for which patients?].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Dr | 2009 |
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.
Topics: Animals; Anti-Inflammatory Agents; Aortic Diseases; Carotid Artery Diseases; Chemokine CCL2; Cyclic | 2010 |
What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Topics: Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Dr | 2010 |
Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidem | 2010 |
[HEADACHES].
Topics: Amyl Nitrite; Carotid Artery Diseases; Classification; Ephedrine; Epinephrine; Ergotamine; Headache; | 1963 |
SUDDEN LOSS OF VISION; DIAGNOSIS AND MANAGEMENT.
Topics: Adrenal Cortex Hormones; Angiomatosis; Anticoagulants; Aortic Diseases; Blindness; Carbonic Anhydras | 1964 |
Atherosclerosis imaging and the future of lipid management.
Topics: Aged; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Coronary Disease; Drug Ther | 2004 |
Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging.
Topics: Adult; Atherosclerosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Angiography; Fema | 2007 |
[Anti-ischemic effect of a new derivative of oxynicotinic acid].
Topics: Animals; Arterial Occlusive Diseases; Brain Ischemia; Carotid Artery Diseases; Free Radicals; Lipid | 1994 |